Detalhe da pesquisa
1.
Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas.
Blood
; 142(22): 1871-1878, 2023 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37494698
2.
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
Blood
; 139(7): 1066-1079, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34699595
3.
A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia.
Br J Haematol
; 201(2): 302-307, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36746431
4.
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival.
Am J Hematol
; 98(3): 413-420, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36588396
5.
A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL).
Am J Hematol
; 98(8): 1277-1285, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37334773
6.
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma.
Am J Hematol
; 98(10): 1540-1549, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37421603
7.
Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis.
Am J Hematol
; 98(1): 49-55, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36226510
8.
Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms.
Blood
; 136(13): 1477-1486, 2020 09 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32640014
9.
Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome.
Am J Hematol
; 97(3): 267-273, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34978743
10.
Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation.
Am J Hematol
; 97(4): 401-410, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35015310
11.
Substratification of patients with newly diagnosed standard-risk multiple myeloma.
Br J Haematol
; 185(2): 254-260, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30768679
12.
Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance.
Blood
; 140(18): 1997-2000, 2022 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36096078
13.
Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.
Am J Hematol
; 94(7): 767-779, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30964202
14.
Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma.
Am J Hematol
; 94(3): 306-311, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30516847
15.
Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study.
Gut
; 67(3): 441-446, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27965284
16.
Outcomes of endoscopic intervention for overt GI bleeding in severe thrombocytopenia.
Gastrointest Endosc
; 88(1): 55-61, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29408558
17.
Time to plateau as a predictor of survival in newly diagnosed multiple myeloma.
Am J Hematol
; 93(7): 889-894, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29659048
18.
Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia.
Blood
; 136(7): 909-913, 2020 08 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32294158
19.
A population-based study of acute panmyelosis with myelofibrosis in the United States: 2004-2015.
Am J Hematol
; 97(4): E144-E147, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35025125
20.
Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma.
Am J Hematol
; 92(8): 752-758, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28383112